Bloomberg BNA's Pharmaceutical Law & Industry Report helps you stay informed of regulatory and litigation developments affecting the pharmaceutical and biotech industries....
Sept. 11 — A Medicare advisory panel Sept. 11 discussed ways to improve the federal program designed to make drug and device company payments to physicians more transparent to the public, with one panelist suggesting disclosures to patients at the time a drug is prescribed.
Rita Redberg, a Medicare Payment Advisory Commission (MedPAC) member and a physician at the University of California, San Francisco, recommended the change during a session on the Centers for Medicare & Medicaid Services' Open Payments transparency initiative. Specifically, the Open Payments program could be improved if doctors disclosed to patients if they have a financial relationship with the maker of a drug or device they are prescribing, Redberg said.
The Open Payments program, created by a provision in the Affordable Care Act, requires manufacturers of drugs, devices and other medical supplies and group purchasing organizations to report certain payments made to physicians or teaching hospitals that are over $10.21.
MedPAC staff presented an analysis of Open Payments program data for 2013 and 2014 that showed the distribution of general payments to doctors from drug or device makers is highly concentrated. For example, the top five percent of physicians that received payments accounted for 86 percent of the total payments, staff said.
After hearing the staff presentation, Francis J. Crosson, the new MedPAC chairman, directed commissioners to recommend improvements the Open Payments program and additional analysis from MedPAC staff on the issue.
Redberg also stressed the importance of increasing patient awareness about financial relationships doctors and hospitals sometimes have with drug and device manufacturers. These relationships “don’t lead to the best medical decisions,” Redberg said.
Other commissioners supported Redberg's point about increasing patient awareness. In a related statement, commissioner Willis (Bill) Gradison, a former Republican member of Congress who now lives in McLean, Va., said the commission hasn't discussed what should be done to influence patient behavior about drug and device companies' payments to providers.
Likewise, commissioner Mary Naylor, a University of Pennsylvania gerontology professor, said the Open Payments database the CMS established is a very important tool, but, by in large, beneficiaries are still unaware of the payments drug and device manufacturers make to providers.
MedPAC held several discussions about drug pricing issues during its September round of meetings. Increasing drug costs are concerning and will be a priority area for Congress's Medicare advisers, Crosson declared Sept. 10. In addition, on Sept. 11, MedPAC devoted an entire session to Medicare drug spending trends.
Staff also presented Sept. 11 an analysis of emergency department services at stand-alone facilities.
To contact the reporter on this story: Michael D. Williamson in Washington at email@example.com
To contact the editor responsible for this story: Kendra Casey Plank at firstname.lastname@example.org
A summary of the Open Payments sessions is at http://tinyurl.com/p8ak3sj.
The Open Payments presentation is at http://tinyurl.com/nh9l9gz.
The presentation on emergency department services at stand-alone facilities is at http://tinyurl.com/pghjpet
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)